Launching Season 3 of the Mindful Leadership Podcast featuring stories of inspirational leaders who do different things differently!
Our inaugural guest on Season 3 is Dr Paul Peter Tak, who is dramatically changing the life of CANCER patients through transformative NEW medicines‼️
He is the CEO of Candel Therapeutics. He is a visionary, a physician, a scientist, an academic, a F500 pharma leader, AND a serial biotech entrepreneur. He has published >600 papers and been cited 100,000+ times‼️ Phew‼️😰
In this episode, we dig into:
✅ His story and what has shaped him
✅ The moment that changed his life forever, and inspired him to be a doctor
✅ The mentor whose advice changed the trajectory of his career
✅ What made him move from being in celebrity in academia to GSK
✅ Why he chose to take a chance on Candel
✅ What drives him. A glimpse into his Purpose
✅ How Candel almost got delisted from NASDAQ‼️
✅ Candel’s turnaround story (truly remarkable!)
✅ The impact - through the lens of patient stories
✅ Biases in medicine (❗️)
✅ A leadership lesson he learnt the hard way
✅ A failure he is proud of and many more great Rapid Fire questions ‼️
✅ His Mindful Leadership Challenge of the month for YOU
So many meaningful stories, so much wisdom, so many great lessons and insights‼️ You won’t want to miss this‼️
About Paul Peter Tak:
Paul Peter Tak, MD PhD FMedSci is President, CEO, Candel Therapeutics (Needham, MA).
He served as Professor of Medicine and founding Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years.
He has published extensively in peer-reviewed journals (>600 publications, H-index 151 [Google Scholar], ~100,000 citations), received numerous awards, has been elected Fellow of the Academy of Medical Sciences, was recognized as 2021 PharmaVOICE100 honoree (100 most inspiring people in life sciences), and included in 'The Medicine Maker Power List’ in 2023 and 2024 (30 influential and inspirational leaders across small molecule, biopharmaceutical, and cell and gene therapy development and manufacture).
At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader. He was the Chair of the Scientific Review Board, the governing body accountable for the scientific assessment of GSK’s R&D portfolio. He is also the founder of GSK’s Immunology Network, a collaboration between GSK and leading academics, which provides the latter with cognitive diversity and privileged access to the latest research and facilities GSK has to offer.
After he became CEO of Candel Therapeutics, he led the company to an Initial Public Offering (IPO) on the Nasdaq. In addition, he has been Board Director, President and CEO of Tempero Pharmaceuticals (acquired by GSK) and Board Director of Galvani Bioelectronics and ViiV Healthcare. He is currently on the Board of Sitryx Therapeutics (Co-founder), Levicept, and Citryll (Chair) as well as on the Board of Trustees of the Lorna & Yuti Chernajovsky Biomedical Research Foundation and the Kennedy Trust for Rheumatology Research.
About Shahana Banerjee:
Shahana is a Certified Executive Coach and part of the elite Forbes Coaches Council.She helps leaders navigate through challenging points of inflection in their business, in their teams, their careers and their own leadership journey. Setup a 30 minute free intro call with her at https://justhuman.io
Learn more about our executive coaching services at https://justhuman.io/coaching/
About Just Human:
Just Human (a boutique people consulting firm) is a growth accelerator for our clients. With over 5 decades of global HR experience, we partner with clients to maximize business results through human centered, ecosystem based people solutions. Visit us at https://justhuman.io/
